EAI045 is primarily used in research settings as a targeted inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), particularly those associated with non-small cell lung cancer (NSCLC). It is specifically designed to address resistance mutations, such as T790M, which often develop in patients treated with first-generation EGFR inhibitors. By selectively binding to these mutated receptors, EAI045 helps to block the signaling pathways that promote cancer cell growth and survival. This makes it a valuable tool in studying resistance mechanisms and developing next-generation therapies for EGFR-driven cancers. Its application is largely confined to preclinical studies, where it aids in understanding the molecular basis of drug resistance and evaluating potential therapeutic strategies.